Cytokinetics to Attend June 2024 Investor Conferences

Cytokinetics, Incorporated, based in South San Francisco, California, has announced its participation in two upcoming investor conferences in June 2024. The biopharmaceutical company will be represented by President and CEO Robert I. Blum, and Executive Vice President and Chief Commercial Officer Andrew Callos.

The first conference is the Jefferies Global Healthcare Conference, taking place at the New York Marriott Marquis Hotel in New York, NY. Blum and Callos will engage in a fireside chat on Wednesday, June 5, 2024, at 2:00 PM Eastern Time. The second event is the 45th Annual Goldman Sachs Healthcare Conference, scheduled for Monday, June 10, 2024, at 11:20 AM Eastern Time at the Loews Miami Beach Hotel in Miami Beach, FL. Both fireside chats will be streamed live on the Cytokinetics website and will be available for replay for 90 days following the events.

Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular treatments. The company focuses on developing muscle activators and inhibitors to treat diseases where cardiac muscle performance is impaired. Their drug candidates aim to improve myocardial muscle function and contractility. One of their leading products, aficamten, is a next-in-class cardiac myosin inhibitor. Following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics is preparing for regulatory submissions for aficamten. This drug is also being evaluated in several other clinical trials, including MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM, targeting various forms of HCM.

Additionally, the company is working on omecamtiv mecarbil, a cardiac muscle activator for heart failure patients. Other notable projects include CK-586, a cardiac myosin inhibitor distinct from aficamten aimed at treating heart failure with preserved ejection fraction (HFpEF), and CK-136, a cardiac troponin activator designed for heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such as right ventricular failure.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!